BioInvent: Important Collaboration with AstraZeneca - Redeye

Redeye views the collaboration with AstraZeneca in lymphoma as another quality stamp for BI-1206. Importantly, it improves BioInvent’s partnering potential, as a similar agreement is already in place with Merck, while AstraZeneca has a history of acquisitions in oncology.

Länk till analysen i sin helhet: https://www.redeye.se/research/976852/bioinvent-important-collaboration-with-astrazeneca?utm_source=finwire&utm_medium=RSS